AZN DCF Analysis: Intrinsic Value $97 vs Price $157

gurufocus.com · 2026-10-05

On October 05, 2026, we delve into the DCF analysis for AstraZeneca PLC (AZN), a company that has experienced a challenging price performance recently, with a y

TickrTrends take: # AZN Valuation Analysis AstraZeneca trades at a significant premium to its discounted cash flow valuation estimate, presenting a notable gap between the DCF-derived intrinsic value and current market price. TickrTrends' undervalued classification suggests the market may be pricing in additional value beyond traditional cash flow projections, potentially reflecting confidence in pipeline assets or market positioning within the Healthcare sector. Investors focused on valuation metrics should monitor whether AZN's operational performance and drug development progress justify the current pricing relative to the intrinsic value estimates.

Read the full story at gurufocus.com →